The optimal timing and courses of bevacizumab added to chemotherapy for non-squamous non-small cell lung cancer: revelations from the real-world experience in a single Chinese cancer center

BACKGROUND: Bevacizumab combined with platinum-based chemotherapy has been approved in the first-line treatment for advanced non-squamous non-small cell lung cancer (NSCLC) without driver genes, but this regimen for second-line or later-line treatment of non-squamous NSCLC remains to be further test...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Ann Transl Med
Autori principali: Long, Qianqian, Feng, Yu, Liu, Chang, Wu, Xianghua, Wang, Huijie, Yu, Hui, Zhao, Xinmin, Wang, Jialei
Natura: Artigo
Lingua:Inglês
Pubblicazione: AME Publishing Company 2020
Soggetti:
Original Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7661884/
https://ncbi.nlm.nih.gov/pubmed/33209891
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/atm-20-6327
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi